Edition:
India

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

3.85USD
22 Nov 2017
Change (% chg)

$0.05 (+1.32%)
Prev Close
$3.80
Open
$3.80
Day's High
$3.95
Day's Low
$3.80
Volume
9,010
Avg. Vol
22,096
52-wk High
$10.15
52-wk Low
$3.28

Select another date:

Wed, Nov 8 2017

BRIEF-Applied Genetic posts qtrly ‍net loss of $0.08​ per share

* Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​

BRIEF-Applied Genetic Technologies reports Q4 revenue of $8.3 mln

* Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S

BRIEF-AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

* AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

BRIEF-Applied Genetic Technologies partners with the Foundation Fighting Blindness

* AGTC and The Foundation Fighting Blindness announce partnership agreement Source text for Eikon: Further company coverage:

BRIEF-AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa

* AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene

BRIEF-AGTC announces FDA orphan drug designation for therapy to treat X-linked retinitis pigmentosa

* AGTC announces U.S. FDA orphan drug designation for gene therapy to treat X-linked retinitis pigmentosa Source text for Eikon: Further company coverage:

BRIEF-AGTC appoints William Sullivan as chief financial officer

* AGTC appoints William Sullivan as chief financial officer, Andrew Ashe named general counsel

BRIEF-Applied Genetic Technologies updates on clinical development of AGTC-402

* Enabling study data published in human gene therapy clinical development support clinical development of AGTC-402 for the treatment of CNGA3-deficient achromatopsia

BRIEF-AGTC announces topline safety data for X-linked retinoschisis phase 1/2 study

* AGTC announces topline safety data for X-linked retinoschisis phase 1/2 study

Select another date: